Zynlonta Market Report 2026

Zynlonta Market Overview

• The Zynlonta market growth in the historic period has been driven by increasing incidence of hematological malignancies, rising failure rates of conventional chemotherapy • Market expansion is supported by increasing development of next-generation adcs, rising demand for personalized cancer treatment • Growth Driver: Rising Lymphoma Incidence Fuels Growth Of The Market • Market Trend: Technological Advancements Propel The Market Growth • North America was the largest region in 2025.

What Is Covered Under Zynlonta Market?

Zynlonta (generic name: loncastuximab tesirine-lpyl) is a prescription medication used in oncology. It is a targeted therapy classified as an antibody-drug conjugate (ADC). Zynlonta is specifically indicated for treating relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. The main types of indications for zynlonta are diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma (NHL) marked by the rapid growth of large B-cells in the lymphatic system, commonly treated with chemotherapy and immunotherapy such as rituximab. It is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, catering to various end users such as adult patients and geriatric patients.

What Is The Zynlonta Market Growth Forecast?

The growth in the forecast period can be attributed to increasing development of next-generation adcs, rising demand for personalized cancer treatment, expansion of targeted oncology pipelines, growing investments in biologic cancer drugs, increasing use of combination cancer therapies. Major trends in the forecast period include increasing adoption of antibody-drug conjugate therapies, rising use of targeted treatments for b-cell lymphomas, growing focus on precision oncology drugs, expansion of hospital-based oncology infusion services, enhanced emphasis on relapsed and refractory cancer treatments.

Global Zynlonta Market Segmentation

1) By Indication: Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma, DLBCL Arising From Follicular Lymphoma 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End-User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Zynlonta Market?

The rising incidence of lymphomas is expected to propel the growth of the zynlonta market going forward. Lymphomas refer to a group of cancers originating in the lymphatic system and primarily affecting lymphocytes, a type of white blood cell found in lymph nodes, the spleen, bone marrow, and other lymphoid tissues. The rising incidence of lymphomas can be attributed to factors such as an aging population, immune system suppression, environmental exposures, viral infections, genetic predispositions, and lifestyle choices. Zynlonta is a targeted therapy used to treat relapsed or refractory large B-cell lymphoma (LBCL) by delivering a chemotherapy drug directly to cancerous B cells, effectively killing them. For instance, according to the American Cancer Society, a US-based non-profit organization, the estimated number of new lymphoma cancer cases increased from 89,010 in 2022 to 89,380 in 2023. Therefore, the rising incidence of lymphomas drive the growth of the zynlonta industry. The rise in clinical trials is expected to propel the growth of the zynlonta market going forward. Clinical trials are research studies conducted with human participants to evaluate medical interventions' safety, efficacy, and effectiveness, including drugs, devices, procedures, or diagnostic tools. The increase in clinical trials is driven by the growing demand for new treatments, advancements in medical research, and the need to address emerging health challenges. Clinical trials help Zynlonta by generating robust clinical evidence that demonstrates its safety and efficacy, supporting regulatory approvals and driving physician confidence in its therapeutic use. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, highlighted that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. This represents an increase of approximately 9.5% in the number of registered trials. Therefore, the rise in clinical trials is driving the growth of the zynlonta industry.

Key Players In The Global Zynlonta Market

Major companies operating in the zynlonta market are ADC Therapeutics SA, Avid Bioservices Inc

Global Zynlonta Market Trends and Insights

The key trend in the zynlonta market is developing innovative therapies, such as combination therapies, to enhance treatment efficacy and improve patient outcomes in cancer care. Combination therapies refer to using two or more treatments, such as drugs or therapies, to enhance therapeutic effectiveness and target multiple aspects of a disease. For instance, in April 2024, ADC Therapeutics, a Switzerland-based biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors, has announced updates on their LOTIS-7 clinical trial, which evaluates Zynlonta (loncastuximab tesirine-lpyl) in combination with bispecific antibodies such as glofitamab or mosunetuzumab. The trial aims to treat heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

Regional Insights

North America was the largest region in the zynlonta market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Zynlonta Market?

The zynlonta market consists of sales of combination therapies, diagnostic and companion tools, supportive care medications, injection kits, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Zynlonta Market Report 2026?

The zynlonta market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the zynlonta industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.